This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 05
  • /
  • CHMP rejects again Nerventra for treatment of Mult...
Drug news

CHMP rejects again Nerventra for treatment of Multiple Sclerosis - Teva

Read time: 1 mins
Last updated: 26th May 2014
Published: 26th May 2014
Source: Pharmawand

Teva Pharmaceutical Industries Ltd and Active Biotech announced that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting Multiple Sclerosis (RRMS) in the European Union (EU) at this time.

Both companies remain committed to the Nerventra (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps.

Brain nerve cells
Brain nerve cells
Learning Zone

Multiple Sclerosis (MS) Learning Zone

Choosing the right treatment is critical to managing multiple sclerosis (MS). Consider your options with the latest data from over 40 MS clinical trial and congress resources.

Read more
How do you prefer to access medical updates and information?
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Blue test tubes arranged in a line, disappearing into the background
Drug news
Moderna reports H5 Flu data
Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.
Read more
Drug news
Cibotercept in PAH ends

Published: 30th May 2025

Read more
Drug news
Khindivi cleared for pediatrics

Published: 30th May 2025

Read more
See all news